Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
about
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant diseaseBendamustine reactivates latent Epstein-Barr virus.Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateA phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphomaAnti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.Follicular dendritic cell sarcoma treated with a variety of chemotherapy.Bendamustine and stem-cell mobilization: not so bad!Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding studySpanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma
P2860
Q33440251-284322E2-34A2-42DE-8E9B-C537CFFAC704Q33911781-3F5C4DF1-068E-4550-8320-46F9A35CC47FQ37094781-C9BDEAC3-F826-46BC-A181-3BF26E8735E0Q38642648-45158452-06A5-457C-85D8-95F0F2124421Q38838789-4C1CF1FE-B4CF-405A-859D-CA42F47FDCFDQ38862949-4E5776D1-FD8B-4072-8BDE-F2440F8F154FQ39938060-93F33B59-9F40-4569-8A56-32E701ABE8B1Q44482782-342DC617-2DA7-4BEB-B3FC-233751F11C71Q49374551-2885545A-DBF2-46C7-847E-758279675C52Q52882277-8D8C2905-8EFD-4BB0-807D-DAE8786040D9Q52895479-833D3213-13DD-47DE-8FDB-04DE472E50C2Q54214982-127E31BE-42A3-4C4D-B936-6DA02961F769Q57162415-45598C43-F7CE-4DCF-9CD9-C95A74AC6C1AQ58767936-56FDEA3F-3227-4050-A41A-DD5A3D6C176D
P2860
Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Bendamustine combined with rit ...... diffuse large B cell lymphoma.
@ast
Bendamustine combined with rit ...... diffuse large B cell lymphoma.
@en
type
label
Bendamustine combined with rit ...... diffuse large B cell lymphoma.
@ast
Bendamustine combined with rit ...... diffuse large B cell lymphoma.
@en
prefLabel
Bendamustine combined with rit ...... diffuse large B cell lymphoma.
@ast
Bendamustine combined with rit ...... diffuse large B cell lymphoma.
@en
P2093
P2860
P1433
P1476
Bendamustine combined with rit ...... diffuse large B cell lymphoma.
@en
P2093
Eric Lynam
Imad A Tabbara
Jeffrey L Vacirca
Peter I Acs
Peter J Rosen
P2860
P304
P356
10.1007/S00277-013-1879-X
P577
2013-08-17T00:00:00Z